Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Add as a preferred source on Google
PLANO, Texas, Feb. 22, 2018 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2017 on Tuesday, March 6, 2018 after market close.
Nuvectra will hold a conference call on Tuesday, March 6, 2018, at 4:30pm ET to discuss the results. The dial-in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 1785806. A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/.
A replay of the call will be available starting on March 6, 2018 through March 13, 2018. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 1785806. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.
About Nuvectra Corporation
NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts:
Nuvectra Corporation
Walter Berger, COO & CFO
(214) 474-3102
[email protected]
Investor Contacts:
The Ruth Group
Tram Bui / Brian Johnston
(646) 536-7035 / 7028
[email protected]
